Mounjaro®
Starting from £179.99/mo
Start journey Learn morePeople across Northern Ireland searching for honest accounts of weight loss injections consistently find the same two medicines at the centre of the conversation: tirzepatide (Mounjaro) and semaglutide (Wegovy). Both are licensed in the UK for weight management, both require a prescription following clinical assessment, and both have a substantial body of clinical trial evidence behind them — not just anecdote. The picture that emerges from that evidence is meaningful, though a prescriber is always the one who decides whether either medicine is right for you specifically.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The gap between headline trial results and individual experience is where most questions live. In SURMOUNT-1, tirzepatide at its highest dose produced an average body-weight reduction of around 20–21% over 72 weeks among adults with obesity. Semaglutide 2.4mg, studied in the STEP 1 trial over 68 weeks, produced an average reduction of around 15%. Both figures come from large, placebo-controlled trials published in the New England Journal of Medicine, with thousands of participants. Those averages matter because they tell you what a broadly similar group of people achieved under controlled conditions, with dietary support alongside the medicine.
What people in Northern Ireland report on forums and in conversation tends to track the trial data fairly closely for the most part. Reduced appetite, especially in the first few weeks, is the near-universal experience. Many people describe losing interest in portion sizes they used to manage automatically. A smaller group finds the GI adjustment harder than expected, nausea after a dose increase being the most common note. That, too, is consistent with the trial safety data: nausea, indigestion and loose stools top the list of reported effects, most pronounced early in treatment or after stepping up a dose, and generally settling within one to two weeks. The NHS medicines page for tirzepatide covers the full side-effect profile in plain language and is worth reading before you start.
One practical thing people mention less often: results plateau if lifestyle changes aren't happening alongside treatment. The trials included dietary support for a reason. The medicine reduces appetite; it doesn't replace a plan.
This is a fair question, and the honest answer is: not always. Verified reviews of regulated pharmacy services can be useful signals, response times, delivery reliability, aftercare quality. Those things vary between providers, and genuine patient feedback on them has value. You can explore broader reviews of weight loss injection services in the UK to get a feel for what matters.
Where reviews become unreliable is when they describe obtaining these medicines cheaply, quickly, and with little clinical involvement. Mounjaro and Wegovy are prescription-only medicines. A review describing frictionless access with no clinical assessment attached isn't describing a safe service, it's describing one you should be cautious of. The MHRA has made this point repeatedly, and in 2025 enforcement operations seized around 20 million doses of illegally traded weight-loss medicines worth approximately £45 million, including a counterfeit tirzepatide manufacturing site found in Northampton. Fake pens have in some cases contained insulin, with hospitalisations resulting.
The reliable test isn't five stars on a review platform. It's whether the pharmacy is registered on the GPhC register. That check takes thirty seconds and tells you whether the service operates under UK regulatory standards. Everything else is secondary.
Northern Ireland sits in an interesting position: NHS access to these medicines is available in principle, but the eligibility criteria are strict and phased. NICE recommended tirzepatide (TA1026, published December 2024) for adults with a BMI of 35 or above plus at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea; from around June 2026, the threshold expanded to include BMI 35–39.9 with four or more qualifying conditions. Waiting times through specialist NHS pathways can be long. For people who don't meet the criteria yet, or who don't want to wait, a regulated private service is the legal alternative.
Private eligibility broadly follows the licensed criteria in the medicine's SmPC: adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition. BMI alone doesn't guarantee approval, a prescriber reviews the whole picture. If you're thinking about the cost side of that, the cost of weight loss injections is worth reading before you commit to anything. One thing consistent across reliable reviews of private services is that a genuinely safe provider builds in clinical oversight at every step, not just at the first consultation.
People ordering before a bank holiday sometimes worry about timing. Worth knowing: a Monday order placed before 12pm, once clinically approved, is dispatched the same day for next-working-day delivery, the bank holiday calendar only affects collection days, so it's worth checking the DPD schedule around public holidays. That kind of practical detail is easy to miss, and a good aftercare team should flag it proactively.
This is the question that ties the thread together. If you're reading accounts of weight loss injection services and trying to work out which matter, look for these markers: Was there a real clinical consultation? Did someone qualified review the answers the same day? Was ID and weight verified? Was there a process for ongoing clinical review before repeat supplies? Was delivery tracked and the packaging discreet?
Those questions separate a reviewed, monitored service from one that's simply filling orders. The Northern Ireland weight loss injections overview covers the access picture in more detail for anyone at the start of that decision. People curious about supplementary treatments sometimes look at what B12 injection users report when combining them with weight loss plans, and a wider range of vitamin B12 injection weight loss reviews can help set realistic expectations about where that approach fits. And if you want to understand how these medicines fit into a broader approach, weight loss treatment options gives a wider lens. Our clinical team's approach is outlined at our prescribers' profile, worth reading if you want to know what clinical oversight actually looks like at a regulated service.
Reviews that mention all of the above, in plain terms, with no suggestion that the clinical bit was optional, are the ones worth taking seriously. If you'd like a prescriber to review your situation, check your eligibility with a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.